Will the American Health Care System Thwart the Covid-19 Antiviral Revolution?

Is a new dawn breaking in the fight against the global pandemic? Now that two major pharmaceutical firms have filed for emergency use authorization for new antiviral pills, we may soon have some valuable arrows in our quiver to fight Covid-19. Per company reports, a short course of Merck’s molnupiravir regimen reduces hospitalizations among infected patients by 50 percent; Pfizer’s Paxlovid curbed admissions by an eye-popping 89 percent—and neither treatment group reported any deaths. The Biden administration has reportedly pumped several billion dollars into the effort, ordering several million...